High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [6]

New England Journal of Medicine

Volumn 358, Issue 1, 2008, Pages 91-93

  Kumar, Shaji ^a   Dispenzieri, Angela ^a   Gertz, Morie A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; IMMUNOGLOBULIN LIGHT CHAIN; MYELOABLATIVE AGENT;

AMYLOIDOSIS; DOSE RESPONSE; DRUG MEGADOSE; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN LIGHT CHAIN GENE; LETTER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; NOTE;

AMYLOIDOSIS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MELPHALAN; MYELOABLATIVE AGONISTS;

EID: 38049048267     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072918     Document Type: Letter

References (3)

1. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357:1083-93.
2. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55.
3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.